Homocysteine and serum markers of immune activation in primary dystonia

Movement Disorders

Volumn 20, Issue 12, 2005, Pages 1663-1667

  Muller, Ulf J ^a   Frick, Barbara ^b   Winkler, Christiana ^b   Fuchs, Dietmar ^b   Wenning, Gregor K ^a   Poewe, Werner ^a   Mueller, Joerg ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Dystonia; Homocysteine; Immune activation; Neopterin

Indexed keywords

BOTULINUM TOXIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; KYNURENINE; NEOPTERIN; TRYPTOPHAN; ANTIPARKINSON AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DYSTONIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNE SYSTEM; IMMUNOREACTIVITY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RATING SCALE; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECT; FOLLOW UP; IMMUNITY; IMMUNOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; ANTI-DYSKINESIA AGENTS; BIOLOGICAL MARKERS; BOTULINUM TOXINS; C-REACTIVE PROTEIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DYSTONIC DISORDERS; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; IMMUNITY; MALE; MIDDLE AGED; VITAMIN B 12;

EID: 33644958056     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20667     Document Type: Article

References (29)

1. Moore AP, Behan PO, Behan WMH. Lymphocyte subset abnormalities in patients with spasmodic torticollis. Acta Neurol Scand 1986;74:371-378.
2. Kumar R, Maraganore DM, Ahlskog JE, Rodriguez M. Treatment of putative immune-mediated and idiopathic cervical dystonia with intravenous methylprednisolone. Neurology 1997;48:732-735.
3. Janavs J, Aminoff MJ. Dystonia and chorea in acquired systemic disorders. J Neurol Neurosurg Psychiatry 1998;65:436-445.
4. Dale RC. Autoimmunity and the basal ganglia: new insights into old diseases. Q J Med 2003;96:183-191.
5. Jankovic J, Patten BM. Blepharospasm and autoimmune diseases. Mov Disord 1987;2:159-163.
6. Rajagopalan N, Humphrey PR, Bucknall RC. Torticollis and blepharospasm in systemic lupus erythematosus. Mov Disord 1989;4:345-348.
7. Muller T, Woitalla D, Hunsdiek A, Kuhn W. Elevated plasma concentrations of homocysteine in dystonia. Acta Neurol Scand 2000;101:388-390.
8. Schröcksnadel K, Frick B, Wirleitner B, Schennach H, Fuchs D. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol 2003; 134: 53-56.
9. Frick B, Schroeksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 2004;37:684-687.
10. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metabolism 2002;3:175-187.
11. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and a1zheimer's disease. N Engl J Med 2202; 346:476-483.
12. Dwyer BE, Raina AK, Perry G, Smith MA. Homocysteine and alzheimer's disease: a modifiable risk? Free Radic Biol Med 2004; 36:1471-1475.
13. Widner B, Leblhuber F, Frick B, Laich A, Artner-Dworzak E, Fuchs D. Moderate hyperhomocysteinaernia and immune activation in Parkinson's disease. J Neural Transm 2002;109:1445-1452.
14. Andrich J, Saft C, Arz A, et al. Hyperhomocysteinaernia in treated patients with huntington's disease. Mov Disord 2004;19:226-228.
15. Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D. Interferon-γ-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Drug Metabolism 2003;10:1401-1411.
16. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2: 245-247.
17. Poewe W, Kleedorfer B. Therapie des essentiellen Blepharospasmus und hemifacialen Spasmus mit lokalen Injektionen von Botulinum Toxin Typ A: Erfahrungen an 50 Patienten. Acta Neurol 1989;16:78-82.
18. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry 1961;4: 561-571.
19. Frick B, Schroecksnadel K, Neurauter G, Wirleitner B, Artner-Dworzak E, Fuchs D. Rapid measurement of total plasma homocysteine by HPLC. Clin Chim Acta 2003;331:19-23.
20. Laich A, Neurauter G, Widner B, Fuchs D. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem 2002;48:579-581.
21. Selhub J, Jaques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third national health and nutrition examination survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999;131:331-339.
22. Molloy AM. Folate and homocysteine interrelationships including genetics of the relevant enzymes. Curr Opin Lipidol 2004;15:49-57.
23. Sibbing D, Asmus F, Koenig IR, et al. Candidate gene studies in focal dystoma. Neurology 2003;61:1097-1101.
24. Mueller J, Kemmler G, Wissel J, et al. The impact of blepharospasm and cervical dystonia on health related quality of life and depression. J Neurol 2002;249:842-846.
25. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocysteine and cardiovascular disease: a critical review of the epidemiological evidence. Ann Intern Med 1999;131:363-375.
26. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002;70:694-702.
27. Ekinci FJ, Malik KU, Shea TB. Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to β-amyloid. J Biol Chem 1999;42:30322-30327.
28. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L. Homocysteine elicits a DNA damage in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20:6920-6926.
29. Shashidharan P, Paris N, Sandu D, et al. Overexpression of TorsinA in PC12 cells protects against toxicity. J Neurochem 2004;88:1019-1025.